Plus Therapeutics (PSTV) 10-Q 12 May 17 2017 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2017	Apr. 30, 2017
Document And Entity Information [Abstract]
Entity Registrant Name	CYTORI THERAPEUTICS, INC.
Entity Central Index Key	1,095,981
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		32,478,201
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q1
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2017

CONSOLIDATED CONDENSED BALANCE

CONSOLIDATED CONDENSED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 6,255	$ 12,560
Accounts receivable, net of reserves of $167 in both 2017 and 2016, respectively	873	1,242
Restricted cash	350	350
Inventories, net	4,107	3,725
Other current assets	500	870
Total current assets	12,085	18,747
Property and equipment, net	3,611	1,157
Other assets	2,008	2,336
Intangibles, net	8,145	8,447
Goodwill	3,922	3,922
Total assets	29,771	34,609
Current liabilities:
Accounts payable and accrued expenses	6,196	5,872
Current portion of long-term obligations, net of discount	6,686	6,629
Total current liabilities	12,882	12,501
Deferred revenues	109	97
Long-term deferred rent and other	17	17
Long-term obligations, net of discount, less current portion	9,400	11,008
Total liabilities	22,408	23,623
Commitments and contingencies (Note 9)
Stockholders’ equity:
Series A 3.6% convertible preferred stock, $0.001 par value; 5,000,000 shares authorized; 13,500 shares issued; no shares outstanding in 2017 and 2016	0	0
Common stock, $0.001 par value; 75,000,000 shares authorized; 23,767,423 and 21,707,890 shares issued and outstanding in 2017 and 2016, respectively	24	22
Additional paid-in capital	392,748	388,769
Accumulated other comprehensive income	1,198	1,258
Accumulated deficit	(386,607)	(379,063)
Total stockholders’ equity	7,363	10,986
Total liabilities and stockholders’ equity	$ 29,771	$ 34,609

CONSOLIDATED CONDENSED BALANCE3

CONSOLIDATED CONDENSED BALANCE SHEETS (UNAUDITED) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Current assets:
Accounts receivable, reserves	$ 167	$ 167
Stockholders’ equity:
Convertible preferred stock	3.60%	3.60%
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	13,500	13,500
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	75,000,000	75,000,000
Common stock, shares issued (in shares)	23,767,423	21,707,890
Common stock, shares outstanding (in shares)	23,767,423	21,707,890

CONSOLIDATED CONDENSED STATEMEN

CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Product revenues	$ 591	$ 1,333
Cost of product revenues (excluding below amortization of intangible assets)	410	468
Amortization of intangible assets	306	99
Gross (loss) profit	(125)	766
Development revenues:
Government contracts and other	1,018	1,585
Total development revenues	1,018	1,585
Operating expenses:
Research and development	3,289	4,127
Sales and marketing	939	1,035
General and administrative	2,108	2,286
Total operating expenses	8,022	7,448
Operating loss	(7,129)	(5,097)
Other income (expense):
Interest income	11	2
Interest expense	(591)	(657)
Other income, net	165	413
Total other expense	(415)	(242)
Net loss	$ (7,544)	$ (5,339)
Basic and diluted net loss per share	$ (0.33)	$ (0.41)
Basic and diluted weighted average shares used in calculating net loss per share	22,736,366	13,086,376
Comprehensive loss:
Net loss	$ (7,544)	$ (5,339)
Other comprehensive loss – foreign currency translation adjustments	(60)	(249)
Comprehensive loss	(7,604)	(5,588)
Azaya Therapeutics, Inc. [Member]
Operating expenses:
In process research and development acquired	$ 1,686	$ 0

CONSOLIDATED CONDENSED STATEME5

CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Cash flows from operating activities:
Net loss	$ (7,544)	$ (5,339)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	442	291
Amortization of deferred financing costs and debt discount	219	232
Joint Venture acquisition obligation accretion	0	17
Provision for expired inventory	340	0
Stock-based compensation expense	199	317
Loss on asset disposal	2	2
Increases (decreases) in cash caused by changes in operating assets and liabilities:
Accounts receivable	335	155
Inventories	7	(206)
Other current assets	(65)	(408)
Other assets	24	(211)
Accounts payable and accrued expenses	(484)	176
Deferred revenues	12	(4)
Long-term deferred rent	0	(80)
Net cash used in operating activities	(4,827)	(5,058)
Cash flows from investing activities:
Purchases of property and equipment /long-lived assets	(5)	(69)
Net cash used in investing activities	(1,163)	(69)
Cash flows from financing activities:
Principal payments on long-term obligations	(1,770)	0
Joint Venture purchase payments	0	(500)
Proceeds from sale of common stock, net	1,435	562
Net cash (used in) provided by financing activities	(335)	62
Effect of exchange rate changes on cash and cash equivalents	20	85
Net decrease in cash and cash equivalents	(6,305)	(4,980)
Cash and cash equivalents at beginning of period	12,560	14,338
Cash and cash equivalents at end of period	6,255	9,358
Cash paid during period for:
Interest	384	400
Azaya Therapeutics, Inc. [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
In process research and development acquired	1,686	0
Cash flows from investing activities:
Purchases of property and equipment /long-lived assets	(1,158)	0
Supplemental schedule of non-cash investing and financing activities:
Common stock issued in payment for the assets acquired	2,311	0
Unpaid liabilities assumed in payment for the assets acquired from Azaya Therapeutics	$ 279	$ 0

Basis of Presentation and New A

Basis of Presentation and New Accounting Standards	3 Months Ended
	Mar. 31, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Basis of Presentation and New Accounting Standards	1. Basis of Presentation and New Accounting Standards Our accompanying unaudited consolidated condensed financial statements as of March 31, 2017 and for the three months ended March 31, 2017 and 2016 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. Our consolidated condensed balance sheet at December 31, 2016 has been derived from the audited financial statements at December 31, 2016, but does not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the financial position and results of operations of Cytori Therapeutics, Inc., and our subsidiaries (collectively, the “Company”) have been included. Operating results for the three months ended March 31, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017. These financial statements should be read in conjunction with the consolidated financial statements and notes therein included in our Annual Report on Form 10-K for the year ended December 31, 2016, filed with the Securities and Exchange Commission on March 24, 2017. On May 10, 2016, following stockholder and Board approval, an amendment (the “Amendment”) to the Company’s amended and restated certificate of incorporation, as amended was filed and declared effective, which Amendment effectuated a one-for-fifteen (1:15) reverse stock split of the Company’s (i) outstanding common stock, and (ii) common stock reserved for issuance upon exercise of outstanding warrants and options (the “1:15 Reverse Stock Split”). Upon effectiveness of the 1:15 Reverse Stock Split, the number of shares of the Company’s common stock (x) issued and outstanding decreased from approximately 200 million shares (as of May 10, 2016) to approximately 13.3 million shares; (y) reserved for issuance upon exercise of outstanding warrants and options decreased from approximately 16 million shares to approximately 1.1 million shares, and (z) reserved but unallocated under our current equity incentive plans (including the stockholder-approved share increase to the Company’s 2014 Equity Incentive Plan) decreased from approximately 6.5 million common shares to approximately 0.4 million common shares. In connection with the 1:15 Reverse Stock Split, the Company also decreased the total number of its authorized shares of common stock from 290 million to 75 million. The number of authorized shares of preferred stock remained unchanged. Following the 1:15 Reverse Stock Split, certain reclassifications have been made to the prior periods’ stockholders’ Reverse Stock Split The Company’s shares of common stock commenced trading on a split-adjusted basis on May 12, 2016. Reclassifications Certain immaterial reclassifications have been made to certain of the prior years’ consolidated financial statements to conform to the current year presentation. Recently Issued and Recently Adopted Accounting Pronouncements Recently Issued Accounting Pronouncements In May 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-12, Revenue from Contracts with Customers In February 2016, the FASB issued ASU 2016-02, Leases In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of certain cash receipts and cash payments In November 2016, the FASB issued Accounting Standards Update No. 2016-18, Restricted Cash In February 2017, the FASB recently issued ASU 2017-04, Simplifying the Test for Goodwill Impairment Recently Adopted Accounting Pronouncements In July 2015, FASB issued ASU 2015-11, Simplifying the Measurement of Inventory In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting In January 2017, the FASB issued Accounting Standards Update No. 2017-01, Clarifying the Definition of a Business

Use of Estimates

Use of Estimates	3 Months Ended
	Mar. 31, 2017
Use Of Estimates [Abstract]
Use of Estimates	2. Use of Estimates The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Our most significant estimates and critical accounting policies involve recognizing revenue, reviewing goodwill and intangible assets for impairment, determining the assumptions used in measuring share-based compensation expense, measuring accretion expense related to our acquisition of the joint venture, measuring expense related to our in process research and development Actual results could differ from these estimates. Management’s estimates and assumptions are reviewed regularly, and the effects of revisions are reflected in the consolidated financial statements in the periods they are determined to be necessary.

Liquidity

Liquidity	3 Months Ended
	Mar. 31, 2017
Liquidity [Abstract]
Liquidity	3. Liquidity We incurred net losses of $7.5 million and for the three months ended March 31, 2017, and $5.3 million and for the three months ended March 31, 2016. We have an accumulated deficit of $386.6 million as of March 31, 2017. Additionally, we have used net cash of $4.8 million and $5.1 million to fund our operating activities for the three months ended March 31, 2017 and 2016, respectively. Further, the Loan and Security Agreement, with Oxford Finance, LCC (“Oxford”), as further described in Note 5, requires us to maintain a minimum of $5.0 million in unrestricted cash and cash equivalents on hand to avoid an event of default under the Loan and Security Agreement. Based on our cash and cash equivalents on hand of approximately $6.3 million at March 31, 2017, and our obligation to make payments of principal of $0.6 million plus accrued interest in monthly installments, we estimate that we must raise additional capital and/or obtain a waiver or restructure the Loan and Security Agreement on or before August 2017 to avoid defaulting under our $5.0 million minimum cash/cash equivalents covenant. To date, these operating losses have been funded primarily from outside sources of invested capital including our recently completed underwritten public offering, Lincoln Park Purchase Agreement with Lincoln Park Capital Fund, LLC (“Lincoln Park”) and the Rights Offering (each defined below), our at-the-market (“ATM”) equity facility, the Loan and Security Agreement and gross profits. We have had, and we will continue to have, an ongoing need to raise additional cash from outside sources to fund our future clinical development programs and other operations. On April 11, 2017, we entered into an underwriting agreement (the “Underwriting Agreement”) with Maxim Group LLC “Maxim”) relating to the issuance and sale of 8.6 million shares of our common stock, par value $0.001 per share. The price to the public in this offering was $1.10 per share. Maxim agreed to purchase the shares from us pursuant to the Underwriting Agreement at a price of $1.0395 per share. The net proceeds to us from the offering were approximately $8.7 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. The offering closed purchase up to 944,000 additional shares of common stock. On June 15, 2016, the Company closed a Rights Offering originally filed under Form S-1 registration statement in April 2016. Pursuant to the Rights Offering, the Company sold an aggregate of 6,704,852 units consisting of a total of 6,704,852 shares of common stock and 3,352,306 warrants, with each warrant exercisable for one share of common stock at an exercise price of $3.06 per share, resulting in total gross proceeds to Cytori of $17.1 million. See Note 12 for further discussion on the June 2016 Rights Offering. Should we be unable to raise additional cash from outside sources, this will have an adverse impact on our operations. The accompanying consolidated financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to its ability to continue as a going concern.

Transactions with Olympus Corpo

Transactions with Olympus Corporation	3 Months Ended
	Mar. 31, 2017
Joint Venture Termination Agreement [Abstract]
Transactions with Olympus Corporation	4. Transactions with Olympus Corporation Under our Joint Venture Termination Agreement (“Termination Agreement”), dated May 8, 2013, with Olympus Corporation (“Olympus”), we were required to pay Olympus a total purchase price of $6.0 million within two years of the date of the Termination Agreement. Pursuant to amendments to the Joint Venture Termination Agreement, dated April 30, 2015 and January 8, 2016, the Company’s repayment obligations were extended through May 8, 2016. We made payments under the Termination Agreement totaling approximately $4.2 million through December 31, 2015, as well as separate payments of $0.5 million each in January 2016 and April 2016, and paid the remaining balance of $0.8 million before the May 8, 2016 due date. There were no outstanding obligations to Olympus as of March 31, 2017 and December 31, 2016.

Long-term Debt

Long-term Debt	3 Months Ended
	Mar. 31, 2017
Debt Disclosure [Abstract]
Long-term Debt	5. Long-term Debt On May 29, 2015, we entered into the Loan and Security Agreement, dated May 29, 2015, with Oxford, pursuant to which it funded an aggregate principal amount of $17.7 million (“Term Loan”), subject to the terms and conditions set forth in the Loan and Security Agreement. The Term Loan accrues interest at a floating rate of at least 8.95% per annum, comprised of three-month LIBOR rate with a floor of 1.00% plus 7.95%. Pursuant to the Loan and Security Agreement, we were previously required to make interest only payments through June 1, 2016 and thereafter we were required to make payments of principal and accrued interest in equal monthly installments sufficient to amortize the Term Loan through June 1, 2019, the maturity date. On February 23, 2016, we received an acknowledgement and agreement from Oxford related to the positive data on our U.S. ACT-OA clinical trial. As a result, pursuant to the Loan and Security Agreement, the period for which we are required to make interest-only payments was extended from July 1, 2016 to January 1, 2017. All unpaid principal and interest with respect to the Term Loan is due and payable in full on June 1, 2019. At maturity of the Term Loan, or earlier repayment in full following voluntary prepayment or upon acceleration, we are required to make a final payment in an aggregate amount equal to approximately $1.1 million. In connection with the Term Loan, on May 29, 2015, we issued to Oxford warrants to purchase an aggregate of 94,441 shares of our common stock at an exercise price of $10.35 per share. These warrants became exercisable as of November 30, 2015 and will expire on May 29, 2025 and, following the authoritative accounting guidance, are equity classified and its respective fair value was recorded as a discount to the debt. The Term Loan is collateralized by a security interest in substantially all of the Company’s existing and subsequently acquired assets, subject to certain exceptions set forth in the Loan and Security Agreement and excluding its intellectual property assets, which are subject to a negative pledge. The minimum liquidity covenant is $5.0 million. As of March 31, 2017, we were in compliance with all of the debt covenants under the Loan and Security Agreement. Our interest expense for the three-months ended March 31, 2017 and 2016 was $0.6 million for both periods. Interest expense is calculated using the effective interest method, therefore it is inclusive of non-cash amortization in the amount of $0.2 million for both periods, related to the amortization of the debt discount, capitalized loan costs, and accretion of final payment.

Revenue Recognition

Revenue Recognition	3 Months Ended
	Mar. 31, 2017
Revenue Recognition [Abstract]
Revenue Recognition	6. Revenue Recognition Concentration of Significant Customers Three direct customers comprised 51% of our revenue recognized for the three months ended March 31, 2017. Two direct customers accounted for 53% of total outstanding accounts receivable (excluding receivables from the Biomedical Advanced Research Development Authority, a division of the U.S. Department of Health and Human Services One distributor and one direct customer comprised 68% of our revenue recognized for the three months ended March 31, 2016. One distributor and two direct customers accounted for 68% of total outstanding accounts receivable as of March 31, 2016. Product revenues, classified by geographic location, are as follows (in thousands): Three months ended March 31, 2017 March 31, 2016 Product Revenues % of Total Product Revenues % of Total Americas $ 148 25 % $ 235 18 % Japan 320 54 % 966 72 % EMEA 112 19 % 132 10 % Asia Pacific 11 2 % — 0 % Total product revenues $ 591 100 % $ 1,333 100 % Research and Development We earn revenue for performing tasks under research and development agreements with governmental agencies like BARDA. Revenues derived from reimbursement of direct out-of-pocket expenses for research costs associated with government contracts are recorded as government contracts and other within development revenues. Government contract revenue is recorded at the gross amount of the reimbursement. The costs associated with these reimbursements are reflected as a component of research and development expense in our statements of operations. We recognized $1.0 million in BARDA revenue for the three months ended March 31, 2017, as compared to $1.6 million for the three months ended March 31, 2016.

Inventories

Inventories	3 Months Ended
	Mar. 31, 2017
Inventory Disclosure [Abstract]
Inventories	7. Inventories Inventories are carried at the lower of cost or net realizable value, determined on the first-in, first-out (FIFO) method. Inventories consisted of the following (in thousands): March 31, 2017 December 31, 2016 Raw materials $ 1,318 $ 885 Work in process 1,039 1,021 Finished goods 1,750 1,819 $ 4,107 $ 3,725

Loss per Share

Loss per Share	3 Months Ended
	Mar. 31, 2017
Earnings Per Share [Abstract]
Loss per Share	8. Loss per Share Basic per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding as calculated using the treasury stock method. Potential common shares were related entirely to outstanding but unexercised options and warrants for all periods presented. We have excluded all potentially dilutive securities, including unvested performance-based restricted stock, from the calculation of diluted loss per share attributable to common stockholders for the three month periods ended March 31, 2017 and 2016, as their inclusion would be antidilutive. Potentially dilutive common shares excluded from the calculations of diluted loss per share was 4.7 million as of March 31, 2017, which includes 3.6 million outstanding warrants and 1.1 million options and restricted stock awards. Potentially dilutive common shares excluded from the calculation of diluted loss per share were 1.1 million for the three months ended March 31, 2016.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2017
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	9. Commitments and Contingencies We have entered into agreements with various research organizations for pre-clinical and clinical development studies, which have provisions for cancellation. Under the terms of these agreements, the vendors provide a variety of services including conducting research, recruiting and enrolling patients, monitoring studies and data analysis. Payments under these agreements typically include fees for services and reimbursement of expenses. The timing of payments due under these agreements is estimated based on current study progress. As of March 31, 2017, we have clinical research study obligations of $2.6 million, We are party to an agreement with Roche Diagnostics Corporation which requires us to make certain product purchase minimums. Pursuant to the agreement, as of March 31, 2017 We are subject to various claims and contingencies related to legal proceedings. Due to their nature, such legal proceedings involve inherent uncertainties including, but not limited to, court rulings, negotiations between affected parties and governmental actions. Management assesses the probability of loss for such contingencies and accrues a liability and/or discloses the relevant circumstances, as appropriate. Management believes that any liability to us that may arise as a result of currently pending legal proceedings will not have a material adverse effect on our financial condition, liquidity, or results of operations as a whole. On February 27, 2017, we entered into a Lease Agreement of office space for our corporate headquarters in San Diego, California (the “Lease”). The initial term of the Lease is 63 months and may be extended upon mutual agreement. We are scheduled to take possession of the premises on November 1, 2017, unless they are earlier occupied by us or the commencement date is delayed to allow for substantial completion of tenant improvements. In connection with the Lease, we issued a letter of credit, or Letter of Credit, in favor of the Landlord in the initial principal amount of approximately $0.1 million, which Letter of Credit and corresponding restricted cash will increase to $0.3 million on June 1, 2017, and to $0.5 million on the commencement date. The Letter of Credit will remain in effect for the term of the Lease. In addition to the base rent, we will also be obligated under the Lease to make certain payments for operating expenses, property taxes, insurance, insurance deductibles and other amounts. On January 27, 2017, we entered into a Lease Agreement of office space for our office in Tokyo, Japan (the “Japan Lease”). The initial term of the Japan Lease is 61 months, and may be extended upon mutual agreement. The Lease commenced on April 15, 2017. We lease facilities for our headquarters office location as well as international office locations. As of March 31, 2017 $7.9 million,

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value	10. Fair Value Measurements Fair value measurements are market-based measurements, not entity-specific measurements. Therefore, fair value measurements are determined based on the assumptions that market participants would use in pricing the asset or liability. We follow a three-level hierarchy to prioritize the inputs used in the valuation techniques to derive fair values. The basis for fair value measurements for each level within the hierarchy is described below: • Level 1: Quoted prices in active markets for identical assets or liabilities. • Level 2: Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets. • Level 3: Valuations derived from valuation techniques in which one or more significant inputs are unobservable in active markets. As of March 31, 2017, Financial Instruments We disclose fair value information about all financial instruments, whether or not recognized in the balance sheet, for which it is practicable to estimate fair value. The disclosures of estimated fair value of financial instruments at March 31, 2017 and December 31, 2016, were determined using available market information and appropriate valuation methods. Considerable judgment is necessary to interpret market data and develop estimated fair value. The use of different market assumptions or estimation methods may have a material effect on the estimated fair value amounts. The carrying amounts for cash equivalents, accounts receivable, other current assets, accounts payable, accrued expenses and other liabilities approximate fair value due to the short-term nature of these instruments. Further, based on the borrowing rates currently available for loans with similar terms, we believe the fair value of long-term debt approximates its carrying value.

Asset Purchase Agreement with A

Asset Purchase Agreement with Azaya Therapeutics	3 Months Ended
	Mar. 31, 2017
Business Combinations [Abstract]
Asset Purchase Agreement with Azaya Therapeutics	11. Asset Purchase Agreement with Azaya Therapeutics On February 15, 2017 (the “Closing Date”), we completed the acquisition from Azaya Therapeutics, Inc. (“Azaya”) of certain tangible assets which consisted of a research lab, equipment and leasehold improvements and the assumption of certain of liabilities of Azaya, pursuant to an Asset Purchase Agreement (the “Agreement”). The book value of the tangible assets acquired was approximately $3.0 million at the acquisition date. The assets acquired are located in a facility rented in San Antonio, TX, by Cytori. In addition, pursuant to the Agreement, we acquired intangible assets comprised of two drug candidates in process research and development (IPR&D) stage (i) ATI-0918, a generic bioequivalent formulation of DOXIL/CAELYX, a chemotherapy drug that is a liposomal encapsulation of doxorubicin (ATI-0918); and (ii) ATI-1123, a liposomal formulation of docetaxel (ATI-1123). At the closing of the acquisition, we (i) issued 1,173,241 of shares of our common stock in Azaya’s name, (A) 879,931 of which were delivered to Azaya promptly after the Closing, and (B) 293,310 of which were deposited into a 15-month escrow pursuant to a standard escrow agreement; and (ii) assumed the obligation to pay approximately $1.8 million of Azaya’s existing payables, of which $1.5 million in payments were made on or prior to March 31, 2017. At the Closing Date, Azaya had no employees and therefore no Azaya employees were transitioned to us. In addition, as of the Closing Date, the Company committed to certain contingent considerations to: (i) pay Azaya fixed commercialization milestone payments based upon achievement of certain net sales milestones for ATI-0918; (ii) make certain earn-out payments to Azaya equal to a mid-single-digit percentage of net sales of ATI-0918; and (iii) make certain earn-out payments to Azaya equal to a low single-digit percentage of net sales of any product (each a “Patented Product”), including ATI-1123, that practices a claim in the related patent assigned by Azaya to the Company (the “ATI-1123 Patent”). Our aggregate earn-out payment obligations to Azaya from global net sales of both ATI-0918 and any Patented Product will not exceed $100.0 million (the “Earn-Out Cap”). Further, the Agreement provides that if we enter into certain assignments, licenses or other transfers of rights to a Patented Product or the ATI-1123 Patent, we will pay Azaya a percentage in the low to mid-teens of the consideration received by us, provided, that our aggregate payment obligation to Azaya for any such assignment, license or other transfer of rights will not exceed $50.0 million. If the Company or its successors, sublicenses or transferees sells a competing product to ATI-0918 at any time prior to satisfaction of the Earn-Out Cap, other than because ATI-0918 fails to receive marketing authorization from the European Medicines Agency within a certain period of time or fails to generate a minimum threshold of net sales within a pre-determined amount of time, then 50% of the net sales of such competing product would be deemed to be net sales of ATI-0918 under the Agreement for purposes of calculating commercialization milestone payments and earn-out payments. We accounted for the acquisition as an asset acquisition because the acquired set of assets did not meet the definition of a business. The total consideration of $4.3 million, which consists of $2.3 million related to the fair value of the common stock issued to Azaya at the acquisition date, $1.8 million in assumed liabilities and $0.2 million in acquisition costs, was allocated to the assets acquired based on their relative fair values at the time of acquisition. All other future payments were deemed contingent consideration which will be accounted for when the contingency is resolved and the consideration is paid or becomes payable. When determining the fair value of tangible assets acquired, the Company estimated the cost to replace the tangible asset with a new asset, taking into consideration such factors as age, condition and the economic useful life of the asset. When determining the fair value of intangible assets acquired, the Company used a discounted cash flow model with key inputs being the applicable discount rate, market growth rates and the timing and amount of future cash flows. The acquired IPR&D is in the early stage of development. Additional research, pre-clinical studies, and regulatory approvals must be successfully completed prior to selling any product. Because there is no current alternative use for the IPR&D, following the authoritative accounting guidance, the Company has expensed it in full on the Closing Date. The Company measured the fair value of the shares issued as consideration in the acquisition of the assets based on the stock price at the acquisition date. Transaction costs directly related to the acquisition of the assets have been capitalized. The total consideration was allocated on a relative fair value basis to the assets acquired, as follows (in thousands): February 15, 2017 Tangible assets $ 2,586 Intangible assets 1,686 Total assets $ 4,272 Accounts payable $ 1,796 Fair value of the common stock issued 2,311 Transaction costs 165 Total consideration $ 4,272

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2017
Stockholders Equity Note [Abstract]
Stockholders' Equity	12 . Pursuant to a registration statement on Form S-1, originally filed on April 6, 2016, as amended (the “Registration Statement”), and declared effective by the U.S. Securities and Exchange Commission (“SEC”) on May 26, 2016, and related prospectus (as supplemented), the Company registered, offered and sold to its participating stockholders of record as of the announced May 20, 2016 record date, one non-transferable subscription right for each share of common stock held by each stockholder as of the record date (the “Rights Offering”). Each right entitled the holder thereof to purchase one unit at the subscription price of $2.55 per unit, composed of one share of common stock and 0.5 of a warrant, with each whole warrant exercisable to purchase one share of common stock at an exercise price of $3.06 per share for 30 months from the date of issuance. Pursuant to the Rights Offering, which closed on June 15, 2016, the Company sold an aggregate of 6,704,852 units, resulting in total net proceeds to the Company of $15.3 million. The warrants issued pursuant to the Rights Offering are currently listed on NASDAQ under the symbol “CYTXW.” Based on the relevant authoritative accounting guidance, the warrants were equity classified at the issuance date. The warrants may be redeemed by the Company at $0.01 per warrant prior to their expiration if the Company’s common stock closes above $7.65 per share for 10 consecutive trading days. On December 22, 2016, we entered into a Purchase Agreement (the “Lincoln Park Purchase Agreement”) with Lincoln Park Capital, LLC (“Lincoln Park”) pursuant to which we have the right to sell to Lincoln Park and Lincoln Park is obligated to purchase up to $20.0 million in amounts of shares, of our common stock, over the 30-month period commencing on the date that a registration statement, which we filed with the SEC in December 2016. We may direct Lincoln Park, at its sole discretion and subject to certain conditions, to purchase up to 100,000 shares of common stock on any business day but in no event will the amount of a single Regular Purchase (as defined in the Lincoln Park Purchase Agreement) exceed $1.0 million. The purchase price of shares of common stock related to the Regular Purchases will be based on the prevailing market prices of such shares at the time of sales. Our sales of shares of common stock to Lincoln Park under the Lincoln Park Purchase Agreement are limited to no more than the number of shares that would result in the beneficial ownership by Lincoln Park and its affiliates, at any single point in time, of more than 9.99% of the then outstanding shares of the common stock. There are no trading volume requirements or restrictions under the Lincoln Park Purchase Agreement. There is no upper limit on the price per share that Lincoln Park must pay for common stock under a Regular Purchase or an accelerated purchase and in no event will shares be sold to Lincoln Park on a day our closing price is less than the floor price of $0.50 per share as set forth in the Purchase Agreement. On December 22, 2016, we issued to Lincoln Park 127,419 shares of common stock with a market value on the date of issuance of approximately $0.2 million as commitment shares in consideration for entering into the Lincoln Park Purchase Agreement. We will issue up to an additional 382,258 shares of common stock on a pro rata basis to Lincoln Park only as and when shares are sold under the Lincoln Park Purchase Agreement to Lincoln Park. Through March 31, 2017, we sold no shares under the Lincoln Park Purchase Agreement. During the three months ended March 31, 2017, we sold 886,292 shares of our common stock under an ATM program, receiving total net proceeds of approximately $1.5 million. During 2016, we sold 1,840,982 shares of our common stock under an ATM program, receiving total net proceeds of approximately $4.4 million. On April 11, 2017, we entered into an underwriting agreement with Maxim relating to the issuance and sale of 8.6 million shares of our common stock, par value $0.001 per share. The price to the public in this offering is $1.10 per share. Maxim agreed to purchase the shares from us pursuant to the Underwriting Agreement at a price of $1.0395 per share. The net proceeds to us from the offering were approximately $8.7 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. The offering closed on April 17, 2017. In addition, under the terms of the underwriting agreement, we have granted Maxim a 45-day option to purchase up to 944,000 additional shares of common stock.

Basis of Presentation and New18

Basis of Presentation and New Accounting Standards (Policies)	3 Months Ended
	Mar. 31, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Basis of Presentation and New Accounting Standards	Our accompanying unaudited consolidated condensed financial statements as of March 31, 2017 and for the three months ended March 31, 2017 and 2016 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. Our consolidated condensed balance sheet at December 31, 2016 has been derived from the audited financial statements at December 31, 2016, but does not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the financial position and results of operations of Cytori Therapeutics, Inc., and our subsidiaries (collectively, the “Company”) have been included. Operating results for the three months ended March 31, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017. These financial statements should be read in conjunction with the consolidated financial statements and notes therein included in our Annual Report on Form 10-K for the year ended December 31, 2016, filed with the Securities and Exchange Commission on March 24, 2017. On May 10, 2016, following stockholder and Board approval, an amendment (the “Amendment”) to the Company’s amended and restated certificate of incorporation, as amended was filed and declared effective, which Amendment effectuated a one-for-fifteen (1:15) reverse stock split of the Company’s (i) outstanding common stock, and (ii) common stock reserved for issuance upon exercise of outstanding warrants and options (the “1:15 Reverse Stock Split”). Upon effectiveness of the 1:15 Reverse Stock Split, the number of shares of the Company’s common stock (x) issued and outstanding decreased from approximately 200 million shares (as of May 10, 2016) to approximately 13.3 million shares; (y) reserved for issuance upon exercise of outstanding warrants and options decreased from approximately 16 million shares to approximately 1.1 million shares, and (z) reserved but unallocated under our current equity incentive plans (including the stockholder-approved share increase to the Company’s 2014 Equity Incentive Plan) decreased from approximately 6.5 million common shares to approximately 0.4 million common shares. In connection with the 1:15 Reverse Stock Split, the Company also decreased the total number of its authorized shares of common stock from 290 million to 75 million. The number of authorized shares of preferred stock remained unchanged. Following the 1:15 Reverse Stock Split, certain reclassifications have been made to the prior periods’ stockholders’ Reverse Stock Split The Company’s shares of common stock commenced trading on a split-adjusted basis on May 12, 2016.
Reclassifications	Reclassifications Certain immaterial reclassifications have been made to certain of the prior years’ consolidated financial statements to conform to the current year presentation.
Recently Issued and Recently Adopted Accounting Pronouncements	Recently Issued and Recently Adopted Accounting Pronouncements Recently Issued Accounting Pronouncements In May 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-12, Revenue from Contracts with Customers In February 2016, the FASB issued ASU 2016-02, Leases In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of certain cash receipts and cash payments In November 2016, the FASB issued Accounting Standards Update No. 2016-18, Restricted Cash In February 2017, the FASB recently issued ASU 2017-04, Simplifying the Test for Goodwill Impairment Recently Adopted Accounting Pronouncements In July 2015, FASB issued ASU 2015-11, Simplifying the Measurement of Inventory In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting In January 2017, the FASB issued Accounting Standards Update No. 2017-01, Clarifying the Definition of a Business
Use of Estimates	The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Our most significant estimates and critical accounting policies involve recognizing revenue, reviewing goodwill and intangible assets for impairment, determining the assumptions used in measuring share-based compensation expense, measuring accretion expense related to our acquisition of the joint venture, measuring expense related to our in process research and development Actual results could differ from these estimates. Management’s estimates and assumptions are reviewed regularly, and the effects of revisions are reflected in the consolidated financial statements in the periods they are determined to be necessary.

Revenue Recognition (Tables)

Revenue Recognition (Tables)	3 Months Ended
	Mar. 31, 2017
Revenue Recognition [Abstract]
Product Revenues, Classified by Geographic Location	Product revenues, classified by geographic location, are as follows (in thousands): Three months ended March 31, 2017 March 31, 2016 Product Revenues % of Total Product Revenues % of Total Americas $ 148 25 % $ 235 18 % Japan 320 54 % 966 72 % EMEA 112 19 % 132 10 % Asia Pacific 11 2 % — 0 % Total product revenues $ 591 100 % $ 1,333 100 %

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2017
Inventory Disclosure [Abstract]
Inventory	Inventories consisted of the following (in thousands): March 31, 2017 December 31, 2016 Raw materials $ 1,318 $ 885 Work in process 1,039 1,021 Finished goods 1,750 1,819 $ 4,107 $ 3,725

Asset Purchase Agreement with21

Asset Purchase Agreement with Azaya Therapeutics (Table)	3 Months Ended
	Mar. 31, 2017
Business Combinations [Abstract]
Summery of Purchase Price Allocation on Fair Value Basis to Identifiable Net Assets	The total consideration was allocated on a relative fair value basis to the assets acquired, as follows (in thousands): February 15, 2017 Tangible assets $ 2,586 Intangible assets 1,686 Total assets $ 4,272 Accounts payable $ 1,796 Fair value of the common stock issued 2,311 Transaction costs 165 Total consideration $ 4,272

Basis of Presentation and New22

Basis of Presentation and New Accounting Standards (Details)	May 10, 2016shares	Mar. 31, 2017shares	Dec. 31, 2016shares	Jun. 15, 2016shares	May 11, 2016shares
Basis Of Presentation And New Accounting Standards [Line Items]
Reverse stock split of common stock	15
Common stock, shares outstanding (in shares)	200,000,000	23,767,423	21,707,890		13,300,000
Number of shares callable by warrants (in shares)	16,000,000			1	1,100,000
Common stock, shares authorized (in shares)	290,000,000	75,000,000	75,000,000		75,000,000
2014 Equity Incentive Plan [Member]
Basis Of Presentation And New Accounting Standards [Line Items]
Number of shares callable by warrants (in shares)	6,500,000				400,000

Liquidity (Details)

Liquidity (Details) - USD ($)	Apr. 11, 2017	Jun. 16, 2016	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016	Jun. 15, 2016	May 11, 2016	May 10, 2016	Dec. 31, 2015
Liquidity [Line Items]
Net loss			$ 7,544,000	$ 5,339,000
Accumulated deficit			386,607,000		$ 379,063,000
Net cash used in operating activities			4,827,000	5,058,000
Cash and cash equivalents			6,255,000	9,358,000	$ 12,560,000				$ 14,338,000
Payments of principal amount in monthly installments			600,000
Minimum cash/cash equivalents covenant			$ 5,000,000
Common stock issued (in shares)		6,704,852
Common stock, par value (in dollars per share)			$ 0.001		$ 0.001
Proceeds from sale of common stock, net			$ 1,435,000	$ 562,000
Each unit consist of number of warrant		3,352,306
Number of shares callable by warrants (in shares)						1	1,100,000	16,000,000
Warrant exercise price (in dollars per share)						$ 3.06
Proceeds from issuance warrants		$ 17,100,000
Common Stock [Member]
Liquidity [Line Items]
Common stock issued (in shares)		6,704,852
Each unit consist of number of warrant			0.5
Number of shares callable by warrants (in shares)			1
Warrant exercise price (in dollars per share)			$ 3.06
Common Stock [Member] | Subsequent Event [Member]
Liquidity [Line Items]
Share issued, price per share	$ 1.10
Common Stock [Member] | Subsequent Event [Member] | Maxim Group LLC [Member]
Liquidity [Line Items]
Common stock issued (in shares)	8,600,000
Common stock, par value (in dollars per share)	$ 0.001
Share issued, price per share	$ 1.0395
Proceeds from sale of common stock, net	$ 8,700,000
Closing of offering date	Apr. 17, 2017
Number of days granted as option to purchase additional shares of common stock to underwriter	45 days
Additional shares of common stock	944,000
Minimum [Member]
Liquidity [Line Items]
Unrestricted cash and cash equivalents			$ 5,000,000

Transactions with Olympus Cor24

Transactions with Olympus Corporation (Details) - USD ($)	Apr. 30, 2015	Mar. 31, 2017	Dec. 31, 2016
Termination of Olympus' Interest in the Joint Venture [Abstract]
Total purchase price	$ 6,000,000
Purchase price payment agreement term		2 years
Amendment One to Joint Venture Termination Agreement [Member]
Termination of Olympus' Interest in the Joint Venture [Abstract]
Purchase price payment termination agreement total	4,200,000
Purchase price principal amount payable on January 31, 2016	500,000
Purchase price principal amount payable on April 30, 2016	500,000
Purchase price principal amount and accrued interest payable on May 8, 2016	$ 800,000
Purchase price payable obligations outstanding balance.		$ 0	$ 0

Long-term Debt (Details)

Long-term Debt (Details) - USD ($)	May 29, 2015	Mar. 31, 2017	Mar. 31, 2016	Jun. 15, 2016	May 11, 2016	May 10, 2016
Debt Instrument [Line Items]
Number of shares callable by warrants (in shares)				1	1,100,000	16,000,000
Warrant exercise price (in dollars per share)				$ 3.06
Minimum liquidity covenant		$ 5,000,000
Interest expense		591,000	$ 657,000
Non-cash amortization		$ 200,000	$ 200,000
LIBOR [Member] | Interest Rate Floor [Member]
Debt Instrument [Line Items]
Basis variable rate	1.00%
Term Loan [Member]
Debt Instrument [Line Items]
Origination Date		May 29, 2015
Original Loan Amount	$ 17,700,000
Basis variable rate	7.95%
Maturity date		Jun. 1, 2019
Fees amount associated with loan	$ 1,100,000
Number of shares callable by warrants (in shares)	94,441
Warrant exercise price (in dollars per share)	$ 10.35
Date from which warrants are exercisable		Nov. 30, 2015
Warrant expiration date		May 29, 2025
Minimum liquidity covenant	$ 5,000,000
Debt instrument, covenant compliance		we were in compliance with all of the debt covenants under the Loan and Security Agreement.
Minimum [Member] | Term Loan [Member]
Debt Instrument [Line Items]
Interest rate	8.95%

Revenue Recognition (Details)

Revenue Recognition (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2017USD ($)Customer	Mar. 31, 2016USD ($)CustomerDistributor
Concentration Risk [Line Items]
Concentration risk percentage	100.00%	100.00%
Revenue recognized | $	$ 1,018	$ 1,585
BARDA Contract [Member]
Concentration Risk [Line Items]
Revenue recognized | $	$ 1,000	$ 1,600
Customer Concentration Risk [Member] | Revenue Recognized [Member]
Concentration Risk [Line Items]
Number of customers | Customer	3	1
Concentration risk percentage	51.00%	68.00%
Number of distributors | Distributor		1
Customer Concentration Risk [Member] | Accounts Receivable [Member]
Concentration Risk [Line Items]
Number of customers | Customer	2	2
Concentration risk percentage	53.00%	68.00%
Number of distributors | Distributor		1

Revenue Recognition - Product R

Revenue Recognition - Product Revenues, Classified by Geographic Location (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Concentration Risk [Line Items]
Revenues	$ 591	$ 1,333
Concentration risk percentage	100.00%	100.00%
Americas [Member]
Concentration Risk [Line Items]
Revenues	$ 148	$ 235
Concentration risk percentage	25.00%	18.00%
Japan [Member]
Concentration Risk [Line Items]
Revenues	$ 320	$ 966
Concentration risk percentage	54.00%	72.00%
EMEA [Member]
Concentration Risk [Line Items]
Revenues	$ 112	$ 132
Concentration risk percentage	19.00%	10.00%
Asia Pacific [Member]
Concentration Risk [Line Items]
Revenues	$ 11
Concentration risk percentage	2.00%	0.00%

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Inventory Disclosure [Abstract]
Raw materials	$ 1,318	$ 885
Work in process	1,039	1,021
Finished goods	1,750	1,819
Inventory, net	$ 4,107	$ 3,725

Loss per Share (Details)

Loss per Share (Details) - shares shares in Millions	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Dilutive common shares excluded from the calculations of diluted loss per share (in shares)	4.7	1.1
Outstanding Warrants [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Dilutive common shares excluded from the calculations of diluted loss per share (in shares)	3.6
Options and Restricted Stock [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Dilutive common shares excluded from the calculations of diluted loss per share (in shares)	1.1

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($) $ in Millions	Jan. 27, 2017	Mar. 31, 2017	Nov. 01, 2017	Jun. 01, 2017	Feb. 27, 2017
Recorded Unconditional Purchase Obligation [Line Items]
Initial term of lease		63 months
Lease commencement date		Nov. 1, 2017
Letter of Credit [Member]
Recorded Unconditional Purchase Obligation [Line Items]
Letter of credit amount required by lease agreement					$ 0.1
Letter of Credit [Member] | Scenario Forecast [Member]
Recorded Unconditional Purchase Obligation [Line Items]
Letter of credit amount required by lease agreement			$ 0.5	$ 0.3
Japan Lease [Member]
Recorded Unconditional Purchase Obligation [Line Items]
Initial term of lease	61 months
Lease commencement date		Apr. 15, 2017
Pre-clinical Research Study Obligations [Member]
Recorded Unconditional Purchase Obligation [Line Items]
Contractual obligation		$ 2.6
Roche Diagnostics Corporation [Member]
Recorded Unconditional Purchase Obligation [Line Items]
Purchase obligation		6.6
Purchase obligation, due in next twelve months		1.1
Operating Lease Obligations [Member]
Recorded Unconditional Purchase Obligation [Line Items]
Contractual obligation		7.9
Contractual obligation, due in next twelve months		$ 1.9

Asset Purchase Agreement with31

Asset Purchase Agreement with Azaya Therapeutics - Additional Information (Details) - Azaya Therapeutics, Inc. [Member]	Feb. 15, 2017USD ($)CandidateEmployeeshares	Mar. 31, 2017USD ($)
Business Acquisition [Line Items]
Obligation to pay on existing payables assumed	$ 1,796,000
Total consideration	4,272,000
Fair value of the common stock issued	2,311,000
Assumed liabilities	1,800,000
Acquisition costs	200,000
Asset Purchase Agreement
Business Acquisition [Line Items]
Book value of tangible assets acquired	$ 3,000,000
Common stock, shares issued | shares	1,173,241
Common stock, shares issued after closing date | shares	879,931
Common stock deposited in escrow | shares	293,310
Obligation to pay on existing payables assumed	$ 1,800,000
Existing payables, paid during the period		$ 1,500,000
Number of employees | Employee	0
Maximum earn-out payment obligations	$ 100,000,000
Aggregate payment obligation threshold limit	$ 50,000,000
Percentage of net sales deemed for purposes of calculating payments	50.00%
Asset Purchase Agreement | IPR&D [Member]
Business Acquisition [Line Items]
Number of drug candidates acquired | Candidate	2

Asset Purchase Agreement with32

Asset Purchase Agreement with Azaya Therapeutics - Summery of Purchase Price Allocation on Fair Value Basis to Identifiable Net Assets (Details) - Azaya Therapeutics, Inc. [Member] $ in Thousands	Feb. 15, 2017USD ($)
Business Acquisition [Line Items]
Tangible assets	$ 2,586
Intangible assets	1,686
Total assets	4,272
Accounts payable	1,796
Fair value of the common stock issued	2,311
Transaction costs	165
Total consideration	$ 4,272

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($)	Apr. 11, 2017	Dec. 22, 2016	Jun. 16, 2016	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016	Jun. 15, 2016	May 11, 2016	May 10, 2016
Common Stock [Abstract]
Each unit consist of number of warrant			3,352,306
Number of shares callable by warrants (in shares)							1	1,100,000	16,000,000
Warrant exercise price (in dollars per share)							$ 3.06
Common stock issued (in shares)			6,704,852
Proceeds from sale of common stock, net				$ 1,435,000	$ 562,000
Common stock issued (in shares)			6,704,852
Common stock, par value (in dollars per share)				$ 0.001		$ 0.001
Proceeds from sale of common stock, net				$ 1,435,000	$ 562,000
Common Stock [Member]
Common Stock [Abstract]
Common Stock Subscription Price				$ 2.55
Each unit consist of number of common stock				1
Each unit consist of number of warrant				0.5
Number of shares callable by warrants (in shares)				1
Warrant exercise price (in dollars per share)				$ 3.06
Period exercisable from the date of issuance				30 months
Common stock issued (in shares)			6,704,852
Gross proceeds from private placement of stock			$ 15,300,000
Redemption price of warrant prior to expiration				$ 0.01
Common stock price per share for warrant redemption				$ 7.65
Number of consecutive trading days for warrant redemption				10 days
Common stock issued (in shares)			6,704,852
Common Stock [Member] | Subsequent Event [Member]
Common Stock [Abstract]
Share issued, price per share	$ 1.10
Common Stock [Member] | Subsequent Event [Member] | Maxim Group LLC [Member]
Common Stock [Abstract]
Common stock issued (in shares)	8,600,000
Proceeds from sale of common stock, net	$ 8,700,000
Common stock issued (in shares)	8,600,000
Common stock, par value (in dollars per share)	$ 0.001
Share issued, price per share	$ 1.0395
Proceeds from sale of common stock, net	$ 8,700,000
Closing of offering date	Apr. 17, 2017
Number of days granted as option to purchase additional shares of common stock to underwriter	45 days
Additional shares of common stock	944,000
Common Stock [Member] | Lincoln Park Capital Fund, LLC [Member]
Common Stock [Abstract]
Period exercisable from the date of issuance		30 months
Common stock issued, value		$ 20,000,000
Common Stock [Member] | Purchase Agreement [Member] | Lincoln Park Capital Fund, LLC [Member]
Common Stock [Abstract]
Common stock issued (in shares)		0
Common stock issued, value		$ 200,000
Common stock issued (in shares)		0
Common Stock [Member] | Securities Purchase Agreement [Member] | Lincoln Park Capital Fund, LLC [Member]
Common Stock [Abstract]
Common stock issued (in shares)		127,419
Trading Volume of Common Shares		0
Common stock issued (in shares)		382,258
Common stock issued (in shares)		127,419
Common Stock [Member] | Maximum [Member] | Purchase Agreement [Member] | Lincoln Park Capital Fund, LLC [Member]
Common Stock [Abstract]
Floor price of per share		$ 0.50
Common Stock [Member] | Maximum [Member] | Single Regular Purchase [Member] | Lincoln Park Capital Fund, LLC [Member]
Common Stock [Abstract]
Common stock issued (in shares)		100,000
Common stock issued (in shares)		100,000
Common Stock [Member] | Minimum [Member] | Lincoln Park Capital Fund, LLC [Member]
Common Stock [Abstract]
Beneficial ownership percentage of common stock outstanding		9.99%
Common Stock [Member] | Minimum [Member] | Single Regular Purchase [Member] | Lincoln Park Capital Fund, LLC [Member]
Common Stock [Abstract]
Common stock issued, value		$ 1,000,000
ATM [Member]
Common Stock [Abstract]
Common stock issued (in shares)				886,292		1,840,982
Proceeds from sale of common stock, net				$ 1,500,000		$ 4,400,000
Common stock issued (in shares)				886,292		1,840,982
Proceeds from sale of common stock, net				$ 1,500,000		$ 4,400,000